April 12, 2022 Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer
April 4, 2022 Trishula Therapeutics Announces Oral Presentation on TTX-030 Anti-CD39 Antibody at American Association for Cancer Research (AACR) Annual Meeting
January 21, 2021 Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
August 26, 2020 Trishula Therapeutics Established to Advance Novel TTX-030, and Anti-CD39 Antibody, Being Evaluated in Phase 1/1B Study in Advanced Cancers
info@trishulatx.com